709 related articles for article (PubMed ID: 31518489)
1. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
2. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A
Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759
[TBL] [Abstract][Full Text] [Related]
4. First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma.
Kim CG; Kim M; Hwang J; Kim ST; Jung M; Kim KH; Kim KH; Chang JS; Koom WS; Roh MR; Chung KY; Kim TM; Kim SK; Lee J; Shin SJ
J Am Acad Dermatol; 2022 Nov; 87(5):989-996. PubMed ID: 36068115
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
[TBL] [Abstract][Full Text] [Related]
6. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
[TBL] [Abstract][Full Text] [Related]
7. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors.
Escuin-Ordinas H; Li S; Xie MW; Sun L; Hugo W; Huang RR; Jiao J; de-Faria FM; Realegeno S; Krystofinski P; Azhdam A; Komenan SM; Atefi M; Comin-Anduix B; Pellegrini M; Cochran AJ; Modlin RL; Herschman HR; Lo RS; McBride WH; Segura T; Ribas A
Nat Commun; 2016 Aug; 7():12348. PubMed ID: 27476449
[TBL] [Abstract][Full Text] [Related]
9. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
10. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
[TBL] [Abstract][Full Text] [Related]
12. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
[TBL] [Abstract][Full Text] [Related]
13. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
14. Trametinib (GSK1120212) in the treatment of melanoma.
Salama AK; Kim KB
Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
[TBL] [Abstract][Full Text] [Related]
15. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
16. Loss of Spry1 reduces growth of BRAF
Montico B; Colizzi F; Giurato G; Rizzo A; Salvati A; Baboci L; Benedetti D; Pivetta E; Covre A; Bo MD; Weisz A; Steffan A; Maio M; Sigalotti L; Fratta E
Cell Death Dis; 2020 May; 11(5):392. PubMed ID: 32444628
[TBL] [Abstract][Full Text] [Related]
17. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
[TBL] [Abstract][Full Text] [Related]
18. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
19. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D
Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316
[TBL] [Abstract][Full Text] [Related]
20. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
Whittaker SR; Theurillat JP; Van Allen E; Wagle N; Hsiao J; Cowley GS; Schadendorf D; Root DE; Garraway LA
Cancer Discov; 2013 Mar; 3(3):350-62. PubMed ID: 23288408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
